Entrada Therapeutics, Inc.
NASDAQ:TRDABiotechnology
+$0.03 today
- Market cap
- $196.93M
- Beta
- -0.26
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.97
Volume 0.82M
Average 0.36M
TRDA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Entrada Therapeutics, Inc.NASDAQ: TRDA
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $4.74M fell 6.7% year over year, behind the -0.0% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 8.9% from the prior quarter. Over 3 fiscal years it compounded at +25.6% a year.
Context
- Stock-based compensation amounted to 77.1% of revenue in FY2025, up 68.6 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -6.7% toward the trailing-twelve-month pace of -0.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 19.61M USD
- Year-over-year change
- +9.5%
- 4-year CAGR
- +66.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.61M | +9.5% |
| FY2024 | 2024-12-31 | 17.92M | +36.6% |
| FY2023 | 2023-12-31 | 13.11M | +32.5% |
| FY2022 | 2022-12-31 | 9.9M | +291.7% |
| FY2021 | 2021-12-31 | 2.53M | — |
Stock-Based Compensation vs competitors
How TRDA compares with its peers on the latest reported figures
- TRDA's LTM Mar 2026 stock-based compensation of $19.27M is the 4th largest of the 11 companies compared; the peer median is $12.02M.
- Its year-over-year change of -0.0% is the 4th highest of 11, against a peer median of -16.0%.
- Stock-based compensation amounts to 335.8% of revenue for TRDA, versus a peer median of 44.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.98B | +32410.1% | +56.9% | — | |
| LTM Mar 2026 | $33.74M | -35.1% | -23.4% | — | |
| LTM Mar 2026 | $23.07M | -33.2% | -6.0% | 50.9% | |
| LTM Mar 2026 | $19.27M | -0.0% | +25.6% | 335.8% | |
| LTM Mar 2026 | $17.5M | -62.1% | -23.7% | — | |
| LTM Mar 2026 | $13.6M | -8.6% | +16.5% | 37.3% | |
| LTM Mar 2026 | $10.44M | +45.6% | +16.4% | 517.7% | |
| LTM Mar 2026 | $9.07M | -23.3% | -16.5% | 4.2% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $6.82M | +13.6% | +50.8% | — |
| LTM Mar 2026 | $5.84M | -6.8% | +38.9% | — | |
| LTM Mar 2026 | $1.52M | -69.5% | — | — | |
| Peer median (excluding TRDA) | $12.02M | -16.0% | +16.4% | 44.1% | |
Competitors are the stored peer set for TRDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (51.16M) | (94.62M) | (6.69M) | 65.63M | (143.75M) |
| Depreciation & Amortization | 1.12M | 1.9M | 2.84M | 3.77M | 4.1M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.53M | 9.9M | 13.11M | 17.92M | 19.61M |
| Change in Working Capital | (3.42M) | (11.11M) | 136.32M | (118.85M) | (4.8M) |
| Accounts Receivables | 0 | 0 | 0 | 2.2M | 2.5M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (715K) | 5.29M | (2.81M) | 991K | (1.8M) |
| Other Working Capital | (2.71M) | (16.4M) | 139.12M | (122.04M) | (5.5M) |
| Other Non-Cash Items | 74K | 151K | (5.78M) | (10.02M) | (3.67M) |
| Operating Cash Flow | (50.86M) | (93.79M) | 139.8M | (41.56M) | (128.51M) |
| Capital Expenditures | (4.58M) | (2.89M) | (5.61M) | (3.16M) | (1.04M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (221.98M) | (407.21M) | (437.72M) | (141.61M) |
| Sales of Investments | 0 | 76.21M | 274.43M | 413.08M | 259.46M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (4.58M) | (148.65M) | (138.4M) | (27.8M) | 116.81M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 190.69M | 479K | 19.41M | 99.61M | 887K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 939K | 0 | 1.63M | 3.36M | 0 |
| Financing Cash Flow | 307.46M | 479K | 21.04M | 102.96M | 887K |
| Effect of Forex Changes | 0 | (3.95M) | 0 | 0 | 0 |
| Net Change in Cash | 252.02M | (245.91M) | 22.45M | 33.61M | (10.82M) |
| Free Cash Flow | (55.44M) | (96.67M) | 134.19M | (44.72M) | (129.55M) |
Entrada Therapeutics, Inc.
NASDAQ:TRDA
Intrinsic Alpha fair value
Locked
Current Price
$5.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.